



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	283649	REDORMIN FORTE
ARTG entry for	Medicine Listed	
Sponsor	SFI Australasia	
Postal Address	PO Box 1027, CROWS NEST, NSW, 1585 Australia	
ARTG Start Date	15/12/2016	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . REDORMIN FORTE

Product Type	Single Medicine Product	Effective Date	25/06/2024
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Helps enhance/promote healthy nerve conduction/transmission/neurotransmission
Traditionally used in Western herbal medicine to soporific/induces sleep
Enhance/promote/increase refreshing sleep
Decrease/reduce/relieve sleeplessness
Traditionally used in Western herbal medicine to decrease/reduce/relieve sleeplessness
Decrease/reduce time to fall asleep
Decrease/reduce/relieve disturbed/restless sleep
Traditionally used in Western herbal medicine to decrease/reduce/relieve disturbed/restless sleep
Enhance/promote/increase healthy sleep patterns
Maintain/support healthy sleeping patterns
Enhance/improve/promote/increase sleep quality/deep sleep
Traditionally used in Western herbal medicine to enhance/improve/promote/increase sleep quality/deep sleep
Help establish/restore/reset sleep-wake cycle (circadian rhythm)

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).
In rare cases, valerian may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine or itching.

Additional Product information



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Pack Size/Poison information	
Pack Size	Poison Schedule
Components	
1 . Formulation 1	
Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Humulus lupulus flower Extract dry concentrate	120 mg
Equivalent: Humulus lupulus (Dry)	720 mg
Valeriana officinalis root Extract dry concentrate	500 mg
Equivalent: Valeriana officinalis (Dry)	2.5 g
Other Ingredients (Excipients)	
colloidal anhydrous silica	
croscarmellose sodium	
hypromellose	
indigo carmine	
macrogol 20000	
magnesium stearate	
microcrystalline cellulose	
stearic acid	
titanium dioxide	

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary